Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

British American Tobacco to launch synthetic nicotine pouches

Published 10/16/2024, 07:14 AM
Updated 10/16/2024, 11:30 AM
© Reuters. A employee holds tobacco leaves during cigarettes manufacturing process in the British American Tobacco Cigarette Factory (BAT) in Bayreuth, southern Germany, April 30, 2014. REUTERS/Michaela Rehle/File Photo
BATS
-
BTI
-

LONDON (Reuters) -British American Tobacco (BAT (LON:BATS)) will launch a version of its Velo nicotine pouches using synthetic nicotine in the United States, David Waterfield, president of the company's U.S. subsidiary Reynolds American (NYSE:RAI), said on Wednesday.

Smoking alternatives like vapes from big tobacco companies, including BAT, usually contain naturally occurring nicotine derived from the tobacco plant, whereas synthetic nicotine is made in a lab from chemicals.

Waterfield said BAT's new Velo product, Velo Plus, due to launch in 2025 and offering more nicotine strengths, contained synthetic nicotine - one of the first clear examples of synthetic nicotine use by a big tobacco company.

"Nicotine derived from tobacco and synthetic nicotine, from a chemical point of view, they are the same," Waterfield told investors at a capital markets event.

He added that BAT would look at other opportunities in synthetic nicotine going forward.

Synthetic nicotine began being used more widely in the United States in recent years as a means to avoid a lengthy application process with the U.S. Food and Drug Administration (FDA), which manufacturers were required to undergo in order to market new nicotine products.

It has so far been used mostly by smaller manufacturers of vapes or nicotine pouches, which users insert under the lip to get a buzz.

Initially, the FDA only had authority over naturally occurring nicotine, so manufacturers of synthetic nicotine products did not have to follow the FDA's application process. The law was changed in April 2022.

Waterfield said that Velo Plus was a product it acquired. An FDA application for the product was submitted by its previous owner before a May 2022 deadline, meaning it can stay on the market while its application is pending.

BAT estimates that the size of U.S. industry-wide vape revenues will grow from around 9 billion pounds ($11.7 billion) today to up to 14 billion pounds by 2030, Waterfield said. It expects U.S. nicotine pouch industry revenues to grow from 1.7 billion pounds to up to 7 billion pounds over the same period.

© Reuters. A employee holds tobacco leaves during cigarettes manufacturing process in the British American Tobacco Cigarette Factory (BAT) in Bayreuth, southern Germany, April 30, 2014. REUTERS/Michaela Rehle/File Photo

BAT sees current U.S. combustible tobacco revenue declines of around 9% as "abnormal", Waterfield said, adding BAT expects U.S. industry revenue growth to settle at around 1% for the rest of the decade.

($1 = 0.7682 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.